BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Caregiver Support Across the Multidisciplinary Care Continuum

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Friday, March 5, 2021
Expiration Date: 
Monday, February 14, 2022
Sponsor Information: 

This program is supported in part by an independent medical education grant from Mitsubishi Tanabe Pharma America, Inc.

Faculty

Ambereen K. Mehta, MD MPH
Ambereen K. Mehta, MD MPH
Assistant Professor
Palliative Care Program, Johns Hopkins Bayview Medical Center
Michelle McWhirter, MSW, LCSW-C
Social Worker
Palliative Care Program, Johns Hopkins Bayview Medical Center
Activity Overview: 

Ambereen Mehta and Michelle McWhirter from Johns Hopkins Medicine provide an overview of important considerations to optimize support for caregivers of adult patients with neuromuscular disease (NMD). The webinar reviews sources of caregiver stress, evolving caregiver needs over the course of disease, the impacts of caregiver strain, strategies to assess caregiver strain, and interventions to manage caregiver strain.

Learning Objectives: 
  • To review sources of caregiver stress
  • To identify caregiver needs as they change with disease progression
  • To explain the impact of caregiver strain
  • To describe how to assess for caregiver strain
  • To provide interventions to manage caregiver strain
Accreditation and Designation Statement: 

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of PeerPoint Medical Education Institute and the Muscular Dystrophy Association.

PeerPoint Medical Education Institute is accredited by the ACCME to provide continuing medical education for physicians. PeerPoint Medical Education Institute designates the enduring format for this educational activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Dates: February 15, 2021 – February 14, 2022

How to Obtain CME credits : 

Once you have viewed the program, MDA will share back with you instructions for how to obtain your CME credits. If you have questions on this process, please reach out to cmemanagement@mdausa.org.

Faculty Disclosures: 

The following presenters, planners, editors, or staff have relevant financial relationships to disclose:

“I, or an immediate family member, have at present or have had within the last 12 months, the following affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation, evaluation, etc. of CME Activities.”

Name: Jonathan Bret Strober, M.D.
Commercial Interest: Biogen
For What Role: Advisory boards, speaker bureau
What was Received: Consulting fees
 
Name: Jonathan Bret Strober, M.D.
Commercial Interest: AveXis
For What Role: Advisory boards, speaker bureau
What was Received: Consulting fees
 
Name: Jonathan Bret Strober, M.D.
Commercial Interest: NS Pharma
For What Role: Advisory board
What was Received: Consulting fees
 
Name: Jonathan Bret Strober, M.D.
Commercial Interest: Momenta
For What Role: Advisory board
What was Received: Consulting fees
 
Name: Jonathan Bret Strober, M.D.
Commercial Interest: Sarepta
For What Role: Advisory board
What was Received: Consulting fees
 

All other presenters, planners, editors, or staff report no relevant relationships to disclose:

“I, or an immediate family member, do not have at present, or within the last 12 months, nor anticipate having financial interest, arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in context to the design, implementation, presentation, evaluation, etc. of CME Activities.”

Educational grants have been received from Mitsubishi Tanabe Pharma America.